Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.49 |
| ▸ | IKZF3 | Q9UKT9 | 7/20 | 0.48 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.48 |
| ▸ | BRD4 | O60885 | 2/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.48 |
| ▸ | TNF | P01375 | 1/20 | 0.48 |
| ▸ | IL1B | P01584 | 1/20 | 0.48 |
| ▸ | MAP1LC3B | Q9GZQ8 | 3/20 | 0.45 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL424062 | 0.90 | CRBN (0.62) | CRBNIKZF3IKZF1BRD4DDB1 | |
| SCHEMBL21602724 | 0.86 | CRBN (0.51) | CRBNIKZF3IKZF1BRD4DDB1 | |
| SCHEMBL25477254 | 0.82 | CRBN (0.52) | CRBNIKZF3IKZF1BRD4DDB1 | |
| SCHEMBL17897664 | 0.82 | CRBN (0.52) | CRBNIKZF3IKZF1BRD4DDB1 | |
| SCHEMBL26141973 | 0.80 | CRBN (0.58) | CRBNIKZF3IKZF1BRD4DDB1 | |
| SCHEMBL13464241 | 0.79 | BRD4 (0.49) | CRBNBRD4DDB1 | |
| SCHEMBL10168336 | 0.78 | CRBN (0.77) | CRBNIKZF3IKZF1BRD4DDB1 | |
| SCHEMBL677652 | 0.77 | CRBN (0.78) | CRBNIKZF3IKZF1BRD4DDB1 | |
| SCHEMBL17246851 | 0.77 | CRBN (0.78) | CRBNIKZF3IKZF1BRD4DDB1 | |
| SCHEMBL13464213 | 0.77 | CRBN (0.57) | CRBNIKZF3IKZF1BRD4DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130211052-A1 | Lenalidomide and Thalidomide Immunoassays | SALADAX BIOMEDICAL INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-8440796-B2 | Lenalidomide and thalidomide immunoassays | SALADAX BIOMEDICAL INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8293492-B2 | Lenalidomide and thalidomide immunoassays | SALADAX BIOMEDICAL INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20120071632-A1 | Lenalidomide and Thalidomide Immunoassays | SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. (CN) | 2012-03-22 | — | — | US | disclosed |
| US-20120064549-A1 | Lenalidomide and Thalidomide Immunoassays | SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. (CN) | 2012-03-15 | — | — | US | disclosed |
| US-8114621-B2 | Lenalidomide and thalidomide immunoassays | SALADAX BIOMEDICAL INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20110223611-A1 | LENALIDOMIDE AND THALIDOMIDE IMMUNOASSAYS | SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. (CN) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071632-A1 | Lenalidomide and Thalidomide Immunoassays | FCGRT, MALT1, SERPINA6 | CRBN 26/4885IKZF3 976/4885IKZF1 388/4885 |
| US-20130211052-A1 | Lenalidomide and Thalidomide Immunoassays | FCGRT, MALT1, SERPINA6 | CRBN 26/4885IKZF3 976/4885IKZF1 388/4885 |
| US-20110223611-A1 | LENALIDOMIDE AND THALIDOMIDE IMMUNOASSAYS | FCGRT, MALT1, SERPINA6 | CRBN 26/4885IKZF3 976/4885IKZF1 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.